Deep vein thrombosis cost-effectiveness of therapy: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{Deep vein thrombosis}} | {{Deep vein thrombosis}} | ||
==Overview== | ==Overview== | ||
In United States, DVT and PE costs are<ref name="pmid17672809">{{cite journal| author=Spyropoulos AC, Lin J| title=Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. | journal=J Manag Care Pharm | year= 2007 | volume= 13 | issue= 6 | pages= 475-86 | pmid=17672809 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17672809 }} </ref>: | In United States, [[deep vein thrombosis]] DVT and [[pulmonary embolism]] PE costs are<ref name="pmid17672809">{{cite journal| author=Spyropoulos AC, Lin J| title=Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. | journal=J Manag Care Pharm | year= 2007 | volume= 13 | issue= 6 | pages= 475-86 | pmid=17672809 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17672809 }} </ref>: | ||
*Initial hospitalization, average more than $9,800 and $14,000 respectively; | *Initial hospitalization, average more than $9,800 and $14,000 respectively; | ||
*Rehospitalization (over half of which occurs within 90 days) costs average more than $11,800 and $14,700, respectively. | *Rehospitalization (over half of which occurs within 90 days) costs average more than $11,800 and $14,700, respectively. | ||
Thus, after major orthopedic surgery, the use of effective VTE prevention strategies can reduce this economic burden. | Thus, after major orthopedic surgery, the use of effective VTE prevention strategies can reduce this economic burden. | ||
On the basis of Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.<ref name="pmid8137188">{{cite journal |author=O'Brien BJ, Anderson DR, Goeree R |title=Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement |journal=CMAJ |volume=150 |issue=7 |pages=1083–90 |year=1994 |month=April |pmid=8137188 |pmc=1486381 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 01:06, 20 June 2012
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ujjwal Rastogi, MBBS [3]; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet
|
Deep Vein Thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Deep vein thrombosis cost-effectiveness of therapy On the Web |
|
Deep vein thrombosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Deep vein thrombosis cost-effectiveness of therapy |
Overview
In United States, deep vein thrombosis DVT and pulmonary embolism PE costs are[1]:
- Initial hospitalization, average more than $9,800 and $14,000 respectively;
- Rehospitalization (over half of which occurs within 90 days) costs average more than $11,800 and $14,700, respectively.
Thus, after major orthopedic surgery, the use of effective VTE prevention strategies can reduce this economic burden.
On the basis of Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.[2]
References
- ↑ Spyropoulos AC, Lin J (2007). "Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations". J Manag Care Pharm. 13 (6): 475–86. PMID 17672809.
- ↑ O'Brien BJ, Anderson DR, Goeree R (1994). "Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement". CMAJ. 150 (7): 1083–90. PMC 1486381. PMID 8137188. Unknown parameter
|month=ignored (help)